Treatment of malignant melanoma with vinblastine (NSC-49842), procarbazine (NSC-77213), and actinomycin D (NSC-3053).
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003609:Dactinomycin / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D011344:Procarbazine / Q000009:adverse effects / Q000627:therapeutic use*; D014747:Vinblastine / Q000009:adverse effects / Q000627:therapeutic use*
D003609:Dactinomycin; D011344:Procarbazine; D014747:Vinblastine